Speaker Profile
M.D., Ph.D., Neurology, MIT
Biography
Diane Chan, MD, Ph.D. (MGH/MIT). Diane is a new Assistant in Neurology at MGH. She earned her M.D.- Ph.D. degrees at Boston University with a focus on Parkinson’s disease for her Ph.D. research. She completed her medical training in Neurology at Yale New Haven Hospital where she was the recipient of the Gilbert Glaser Award and a R25 NINDS Research Fellowship from the NIH. She completed a fellowship at MGH and Brigham and Women’s Hospital in 2019. She is now seeing patients in the FTD Unit in Memory Disorders and Comprehensive Neurology at the Massachusetts General Hospital while concurrently conducting post-doctoral research at MIT in Li-Huei Tsai’s laboratory to translate two different non-invasive brain stimulation technologies for the potential treatment of Alzheimer’s disease and Parkinson’s disease into human use. She is currently matriculated in the Harvard Catalyst Clinical and Translational Research Academy at Harvard Medical School.
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
Ira Mellman, Medici Therapeutics
PMWC Award Ceremony
• Jedd D. Wolchok, Weill Cornell Medicine
• Suzanne Topalian, Johns Hopkins
• Levi Garraway, Roche
Keynote: Future Breakthroughs in Immuno-Oncology: New Targets, Modalities & Combinations
• Levi Garraway, Roche
Checkpoint 2.0 in Practice: PD-1+VEGF Wins, Resistance Salvage & Biomarker Gates
• Chair: Anne Kasmar, Parexel
• Jedd D. Wolchok, Weill Cornell Medicine
• Roy S. Herbst, Yale
• Nathan Fowler, BostonGene
Immunotherapy with Personalized Cancer Vaccines: Who, When, How Fast?
• Chair: Suzanne Topalian, Johns Hopkins
• Tal Zaks, Orbimed
• Lelia Delamarre, Genentech
The Next Era: Neutralizing On-Target, Off-Tumor Effects by Turning Cancer Against Itself
• Cyriac Roeding, Earli
Fireside Chat: Immune Tolerance to Cure, A Conversation With...
• Lee Hood, Institute for Systems Biology
• Mary E. Brunkow, Institute for Systems Biology
ADCs in the Checkpoint Era: Who Benefits, What to Combine, What to Avoid
• Chair: Shreya Badhrinarayanan, Pfizer
• Gerold Meinhardt, Daiichi Sankyo
• Vadim Koshkin, UCSF
Strategic IP Management in Cell and Gene Therapy: Navigating Legal and Practical Challenges
• Janet Xiao, Morrison & Foerster LLP
Targeting the Tumor Microenvironment (TME) in Practice: Biomarkers & Combos
• Chair: Ira Mellman, Medici Therapeutics
• Dmitry Gabrilovich, AstraZeneca
• Jennifer Mataraza, Novartis
• Nathan Fowler, BostonGene
• Christine Moussion, Genentech
Future Breakthroughs in TME Reprogramming: New Modalities, Smarter Delivery & Overcoming Resistance
• David Kirn, ReIGNITE
Radiopharmaceutical Therapy: New Targets, Isotopes, and Challenges
• Chair: William Oh, Yale
• Munir Ghesani, United Theranostics
• Sandy Srinivas, Stanford
• Anna Karmann, AdvanCell
